France Crispr And Cas Genes Market Size & Outlook
France crispr and cas genes market, 2018-2030 (US$M)
Related Markets
France crispr and cas genes market highlights
- The France crispr and cas genes market generated a revenue of USD 170.4 million in 2024 and is expected to reach USD 401.7 million by 2030.
- The France market is expected to grow at a CAGR of 15.5% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Crispr and cas genes market data book summary
| Market revenue in 2024 | USD 170.4 million |
| Market revenue in 2030 | USD 401.7 million |
| Growth rate | 15.5% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, France accounted for 3.6% of the global crispr and cas genes market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany crispr and cas genes market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 688.9 million by 2030.
Product was the largest segment with a revenue share of 89.5% in 2024. Horizon Databook has segmented the France crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Strategic initiatives undertaken by French biotechnology and agri-biotech companies to increase penetration of CRISPR gene editing technology are expected to boost revenue generation of the country’s market.
Under this agreement, Vilmorin & Cie received a license to access CRISPR-Cas9 patents of Corteva that covered genome editing tools for agricultural use. This allowed Vilmorin & Cie to deploy it in vegetable and field seeds-related research work & commercial applications.
Such initiatives have strengthened the company’s ability to develop more efficient seed varieties, consequently, expanding the usage of CRISPR technology across the French agriculture industry. Moreover, numerous patent approvals by regulatory agencies are expected to drive the importance of CRISPR technology in France.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France crispr and cas genes market size, by product & service, 2018-2030 (US$M)
France CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
